With regards to helping patients as well as the business model, the viral vector is interesting because in theory it does not just have to be applied to HIV patients. If leronlimab is proven effective, would it make sense to offer this gene therapy to have the body produce leronlimab on its own as a super vitamin, anti-aging therapy for many people in the population. If so, how do you price it. Who would qualify. There are only a handful of approved gene therapies in the past 5 years most priced at about 1 million a treatment.

What may be uniqie about leronlimab versus other drugs like keytruda is the potential broad systemic benefit towards multiple diseases along with a pristine safety profile which possibly gives the rationale towards a broadly administered gene therapy. For example, if HIV patients are the only ones who qualify, and they then start outliving everyone in the general population including the delta32 homozygous mutation patients (the theory is that leronlimab immunomodulates just right which may make it more therapeutic than the delta32 homozygous mutation), will others demand it as well. What will be the impact towards staggard patents for several conditions that might expire 20 years apart. What will this do towards the overal cost of health care and human longevity?

I suppose if the above becomes true, it would be a good propblem to have for patients and shareholders.